Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Chi Sheng Pharma & Biotech Co's PB Ratio or its related term are showing as below:
ROCO:4111'
s PB Ratio Range Over the Past 10 Years
Min: 1.12 Med: 1.31 Max: 1.66
Current: 1.31
During the past 13 years, Chi Sheng Pharma & Biotech Co's highest PB Ratio was 1.66. The lowest was 1.12. And the median was 1.31.
ROCO:4111's PB Ratio is ranked better than 69.5% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs ROCO:4111: 1.31
During the past 12 months, Chi Sheng Pharma & Biotech Co's average Book Value Per Share Growth Rate was 8.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 3.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Chi Sheng Pharma & Biotech Co was 7.60% per year. The lowest was 0.70% per year. And the median was 4.20% per year.
Back to Basics: PB Ratio
Chi Sheng Pharma & Biotech Co (ROCO:4111) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Chi Sheng Pharma & Biotech Co PB Ratio Related Terms
Chi Sheng Pharma & Biotech Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Chi Sheng Pharma & Biotech Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chi Sheng Pharma & Biotech Co PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Chi Sheng Pharma & Biotech Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Chi Sheng Pharma & Biotech Co's PB Ratio falls into.
Chi Sheng Pharma & Biotech Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Chi Sheng Pharma & Biotech Co (ROCO:4111) has a PB Ratio of 1.31 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Chi Sheng Pharma & Biotech Co and its competitors. This is near median its historical median of 1.31. Over the past decade, Chi Sheng Pharma & Biotech Co's PB Ratio has ranged from 1.12 to 1.66. According to the industry distribution chart, Chi Sheng Pharma & Biotech Co ranks #240 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 30.5%.
Is Chi Sheng Pharma & Biotech Co's PB Ratio too high?
Chi Sheng Pharma & Biotech Co's current PB Ratio of 1.31 is near median its 10-year median of 1.31. Over the past 10 years, this metric has ranged from a low of 1.12 to a high of 1.66. The Medical Devices & Instruments industry median PB Ratio is 2.05. Chi Sheng Pharma & Biotech Co's value of 1.31 is 36.1% below this industry median. Based on the distribution chart, Chi Sheng Pharma & Biotech Co ranks #240 out of 787 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Chi Sheng Pharma & Biotech Co has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chi Sheng Pharma & Biotech Co's PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Chi Sheng Pharma & Biotech Co ranks #240 out of 787 companies for PB Ratio. This puts Chi Sheng Pharma & Biotech Co in the upper half of its industry. The industry median PB Ratio is 2.05. Chi Sheng Pharma & Biotech Co's value of 1.31 is 36.1% below this benchmark. Historically, Chi Sheng Pharma & Biotech Co's own PB Ratio has ranged from 1.12 to 1.66 over the past decade. While the company's 10-year median is 1.31 vs. the industry median of 2.05, Chi Sheng Pharma & Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chi Sheng Pharma & Biotech Co's current PB Ratio of 1.31 is 36.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Chi Sheng Pharma & Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chi Sheng Pharma & Biotech Co's current PB Ratio is 1.31, which is near median its own 10-year median of 1.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chi Sheng Pharma & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co (ROCO:4111) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.14, compared to a current price of NT$30.15 — trading 9% below its estimated fair value. The current PB Ratio is 1.31, which is near median its 10-year median of 1.31 and 36.1% below the Medical Devices & Instruments industry median of 2.05. Chi Sheng Pharma & Biotech Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Chi Sheng Pharma & Biotech Co (ROCO:4111), the current PB Ratio is 1.31 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chi Sheng Pharma & Biotech Co (ROCO:4111) Overvalued in 2026?
Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co stock appears to be undervalued.
The current stock price of NT$30.15 is trading 9% below its estimated GF Value™ of NT$33.14.
GuruFocus considers Chi Sheng Pharma & Biotech Co to be Fairly Valued.
Key valuation signals for ROCO:4111:
PB Ratio: 1.31 (near median its 10-year median of 1.31)
GF Value™: NT$33.14 vs. price of NT$30.15 (9% below fair value)
Industry Position: 36.1% below the Medical Devices & Instruments median (#240 of 787)
No single metric tells the full story. See the ROCO:4111 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chi Sheng Pharma & Biotech Co Business Description
Chi Sheng Pharma & Biotech Co Ltd manufactures and distributes medical medicines and equipment in Taiwan. It offers injections, including hemodialysis solutions, amino acid injections, vitamin injections, and externally applied medicines.
84GF Score
Get the complete analysis for ROCO:4111
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4111 has been successfully added to your 
